Stella Pharma Corp. () Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: Stella Pharma Corp. has changed its score on 05 Dec 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Operating profit has grown by an annual rate -234.76% of over the last 5 years

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JPY 13,307 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.70

Return on Equity

-4.45%

Price to Book

4.36

Revenue and Profits:

Net Sales:

92 Million

(Quarterly Results - Jun 2025)

Net Profit:

-157 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-32.51%

6 Months

-36.34%

1 Year

-53.75%

2 Years

-13.03%

3 Years

-55.97%

4 Years

-57.34%

5 Years

0.0%

Stella Pharma Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Stella Pharma Corp. Hits Day Low at JPY 266 Amid Price Pressure

Stella Pharma Corp. has faced notable volatility, with a significant stock decline today and a substantial drop over the past week and month. Year-to-date, the stock has decreased sharply, reflecting ongoing financial challenges, including negative returns and operating profit growth. The company’s performance lags behind the broader market.

Stella Pharma Corp. Hits Day Low at JPY 299 Amid Price Pressure

Stella Pharma Corp. has faced notable stock volatility, hitting an intraday low and experiencing significant declines over various time frames. The company's financial indicators reflect ongoing challenges, including negative returns and poor operating profit growth, contributing to its underperformance compared to the Japan Nikkei 225.

Stella Pharma Hits Day Low at JPY 349 Amid Price Pressure

Stella Pharma Corp. has faced notable volatility, with a significant stock decline on October 14, 2025. The company has struggled financially, reporting a year-to-date drop and a negative EBITDA. Its long-term performance reflects ongoing challenges in operational efficiency and profitability, amidst contrasting trends in the broader market.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

65.01%

EBIT Growth (5y)

-234.76%

EBIT to Interest (avg)

-188.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.76

Sales to Capital Employed (avg)

0.11

Tax Ratio

2.13%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.85

EV to EBIT

-109.86

EV to EBITDA

-178.57

EV to Capital Employed

12.91

EV to Sales

10.32

PEG Ratio

Dividend Yield

ROCE (Latest)

-11.75%

ROE (Latest)

-4.39%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -86.93% vs 734.71% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -167.31% vs 321.93% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "92.40",
          "val2": "707.00",
          "chgp": "-86.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-144.60",
          "val2": "294.60",
          "chgp": "-149.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.50",
          "val2": "1.30",
          "chgp": "15.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-156.70",
          "val2": "232.80",
          "chgp": "-167.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,643.20%",
          "val2": "402.80%",
          "chgp": "-204.60%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 256.62% vs 17.63% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 81.56% vs 1.94% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "961.10",
          "val2": "269.50",
          "chgp": "256.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-55.50",
          "val2": "-725.30",
          "chgp": "92.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "2.10",
          "chgp": "95.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-140.80",
          "val2": "-763.70",
          "chgp": "81.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-93.90%",
          "val2": "-2,821.20%",
          "chgp": "272.73%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

92.40

707.00

-86.93%

Operating Profit (PBDIT) excl Other Income

-144.60

294.60

-149.08%

Interest

1.50

1.30

15.38%

Exceptional Items

0.00

Consolidate Net Profit

-156.70

232.80

-167.31%

Operating Profit Margin (Excl OI)

-1,643.20%

402.80%

-204.60%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -86.93% vs 734.71% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -167.31% vs 321.93% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

961.10

269.50

256.62%

Operating Profit (PBDIT) excl Other Income

-55.50

-725.30

92.35%

Interest

4.10

2.10

95.24%

Exceptional Items

0.00

Consolidate Net Profit

-140.80

-763.70

81.56%

Operating Profit Margin (Excl OI)

-93.90%

-2,821.20%

272.73%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 256.62% vs 17.63% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 81.56% vs 1.94% in Mar 2024

All Annual Results

Company CV

About Stella Pharma Corp.

Stella Pharma Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Stella Pharma Corp.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor Management Efficiency with a low ROE of 0%

Poor long term growth as Operating profit has grown by an annual rate -234.76% of over the last 5 years

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Stella Pharma Corp. Hits Day Low at JPY 266 Amid Price Pressure

Stella Pharma Corp. Hits Day Low at JPY 299 Amid Price Pressure

Stella Pharma Hits Day Low at JPY 349 Amid Price Pressure

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Mar'25

About Stella Pharma Corp.

Company Coordinates